Key Takeaways
- Portal Biotech raised $35M in Series A funding, led by NATO Innovation Fund and Earlybird Venture Capital.
- Funds will be used to accelerate the company’s roadmap and expand R&D and data science teams.
- Portal’s technology enables single-molecule sequencing of proteins, enhancing understanding of protein biology.
Funding Details
Portal Biotech, a biotechnology firm based in London, has successfully raised $35 million in Series A funding. This round was spearheaded by the NATO Innovation Fund and Earlybird Venture Capital, with contributions from existing investors like SCVC, Pillar VC, 8VC, Amino Collective, and Outsized. New investors, including We Venture Capital, British Business Bank, and WS Investment Company, also joined the funding round.
Company Vision
The investment will primarily be directed towards enhancing Portal Biotech’s ongoing projects. The company aims to deepen collaborations with other pharmaceutical and biotech innovators while expanding its research and development, engineering, and data science teams.
CEO Andy Heron leads Portal Biotech, which focuses on providing an advanced platform for sequencing intact full-length proteins at the single-molecule level. This innovative technology allows for a comprehensive characterization of protein mutations and modifications. By integrating advanced artificial intelligence methods, Portal’s platform offers researchers unprecedented insights into the complexities of the proteome that conventional technologies fail to deliver.
Impact on Protein Biology
With the advancement of this technology, Portal Biotech aims to establish foundational AI models that enhance understanding of both protein biology and the broader life sciences. The insights gained through their platform could significantly impact research and development in various biological fields, providing a more dynamic understanding of proteins and their roles within biological systems.
The content above is a summary. For more details, see the source article.
